Study for the effects of vildagriptin in combination with metformin on vascular endothelial function and systemic metabolism in patients with type 2 diabetes -multicenter, prospective, randomized, open-label, parallel group comparison
- Conditions
- type 2 diabetes mellitus
- Registration Number
- JPRN-UMIN000011063
- Lead Sponsor
- Study group for the treatment of type 2 diabetes in Sapporo
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 110
Not provided
1) patients who receive insulin injection therapy, 2) severe respiratory disease, renal dysfunction and heart disease, 3) moderate or severe renal dysfunction (1.3 and 1.2 mg/dL or more for male and female, respectively), 4) hepatitis or hepatocirrhosis (AST/GOT or ALT/GPT: 100U or more), 5) malignant tumor, 6) history of angina, myocardial infarction, stroke or arteriosclerotic diseases, 7) patients who receive thiazolidinediones, alpha-glucosidase inhibitor, GLP-1 receptor agonist or DPP-4 inhibitor in 8 weeks, 8) hypersensitivity to study drugs on this study, 9) pregnancy, nursing woman or possibly pregnant woman, 10) patients who are inadequate to enter this study due to the other reasons by physician's judgments
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method